DAEWOONG CO.,LTD
Founded in 1961 and listed in 1973, Daewoong is a KOSPI holding company managing 35 subsidiaries including Daewoong Pharmaceutical.
As of 2026-10-11, DAEWOONG CO.,LTD has 12 Korean MFDS device approvals, 21 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureEstablished in 1961 and listed on the KOSPI in 1973, Daewoong Co., Ltd. is a holding company whose subsidiaries include Daewoong Pharmaceutical, Daewoong Bio, and HanAll Biopharma. Its core businesses are investment activities and management services, and as of December 31, 2025 it held a total of 35 subsidiaries, including Daewoong Pharmaceutical, Daewoong Bio, and HanAll Biopharma. Operating revenue consists of service fees, royalties, and dividends collected from subsidiaries and other invested companies; in its 66th fiscal term (2025), consolidated revenue reached KRW 2.0684 trillion (up 6.8% year-on-year), operating profit was KRW 261.8 billion (down 7.1%), and net income was KRW 227.9 billion (up 231.0%).
Regulatory approvals
data.go.kr12 Korean MFDS device approvals · 2002–2005
- MFDS의료용물질생성기Revoked2005-04-09Product approval · Class 2제허 05-255 호
- MFDS개인용온열기Revoked2005-01-25Product approval · Class 2제허 05-69 호
- MFDS의료용진동기Revoked2004-12-24Product approval · Class 2제허 04-1280 호
- MFDS의료용진동기Revoked2004-10-20Product approval · Class 2제허 04-1074 호
- MFDS개인용조합자극기Revoked2004-08-17Product approval · Class 2제허 04-854 호
- MFDS개인용조합자극기Revoked2003-06-02Product approval · Class 2제허 03-467 호
- MFDS개인용온열기Revoked2002-12-09Product approval · Class 2제허 02-943 호
- MFDS개인용조합자극기Revoked2002-11-22Product approval · Class 2제허 02-906 호
- MFDS의료용진동기Revoked2002-09-02Product approval · Class 2제허 02-715 호
- MFDS개인용조합자극기Revoked2002-08-27Product approval · Class 2제허 02-696 호
- MFDS의료용진동기Revoked2002-06-28Product approval · Class 2제허 02-531 호
- MFDS개인용조합자극기Revoked2002-03-20Product approval · Class 2제허 02-232 호
Clinical trials
data.go.kr7 MFDS clinical trial authorisations · 2012–2017 (Bioequivalence 5 · Phase 1 1 · Phase 3 1)
- Phase 1메트포르민염산염, 아토르바스타틴칼슘2017-02-07
1 trial site
- Phase 3메트포르민염산염, 아토르바스타틴칼슘2015-03-19
36 trial sites
- BioequivalenceDWJ1333-1정2014-05-01
2 trial sites
- Bioequivalence대웅올메사탄플러스정20/12.5밀리그램2013-12-10
2 trial sites
- BioequivalenceDWJ1334정 20밀리그램(올메사탄메독소밀)2013-12-03
2 trial sites
- BioequivalenceDWJ1333정2013-09-04
- Bioequivalence대웅콜린알포세레이트연질캡슐 400mg2012-07-31
2 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matched- Subsidiary: 대웅바이오Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease
Phase 4 · Unknown · 2022-01 · NCT05383183
- Subsidiary: 대웅바이오Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects
Phase 1 · Completed · 2019-03 · NCT05219461
Key disclosures
KRX KIND via OpenDARTShow 17 more events
Publications
PubMed · affiliation-matched- Crystal structure of Fis1 and Bap31 provides information on protein-protein interactions at mitochondria-associated ER membranes.
Communications biology · 2025-08 · Nguyen MD, Kim Y, Bae SH 외 9
- Canine Stem Cell-derived Exosomes for Lung Inflammation: Efficacy of Intratracheal Versus Intravenous Administration in an Acute Lung Injury Mouse Model.
In vivo (Athens, Greece) · 2025-01 · Oh HN, Kim YS, Lim GH 외 4
- Evaluation of cognitive and mobility function in geriatric dogs following treatment with stem cell and stem cell extracellular vesicles derived from embryonic stem cells: a pilot study.
Frontiers in veterinary science · 2025-01 · Kim TY, Kim NH, Chae JA 외 6
- Ocular and Plasma Pharmacokinetics of Enavogliflozin Ophthalmic Solution in Preclinical Species.
Pharmaceuticals (Basel, Switzerland) · 2024-01 · Jang M, Kang M, Lee E 외 1
- Flow Synthesis of L-α-Glycerylphosphorylcholine: Studies on Synthetic Routes Applicable to a Flow Reactor and Optimization of Reaction Conditions.
Pharmaceutics · 2022-11 · Park J, Lee S, Kim G 외 3
- Removal of Inorganic Salts in Municipal Solid Waste Incineration Fly Ash Using a Washing Ejector and Its Application for CO2 Capture.
International journal of environmental research and public health · 2022-02 · Kim H, Purev O, Cho K 외 3
- Long-chain polyphosphates impair SARS-CoV-2 infection and replication.
Science signaling · 2021-07 · Ferrucci V, Kong DY, Asadzadeh F 외 32
- Analysis of diagnostic decision in acupuncture from the actual functional dyspepsia patient's clinical information.
Integrative medicine research · 2020-12 · Kim SY, Hong SH, Park JW 외 9
- Predicting risk of type 2 diabetes mellitus in Korean adults aged 40-69 by integrating clinical and genetic factors.
Primary care diabetes · 2019-02 · Kim SH, Lee ES, Yoo J 외 1
- Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects.
Drug design, development and therapy · 2019-01 · Oh M, Shin JG, Ahn S 외 5
Show 11 more publications
- Two-Week Exclusive Supplementation of Modified Ketogenic Nutrition Drink Reserves Lean Body Mass and Improves Blood Lipid Profile in Obese Adults: A Randomized Clinical Trial.
Nutrients · 2018-12 · Choi HR, Kim J, Lim H 외 1
- Epidermal Growth Factor Relieves Inflammatory Signals in Staphylococcus aureus-Treated Human Epidermal Keratinocytes and Atopic Dermatitis-Like Skin Lesions in Nc/Nga Mice.
BioMed research international · 2018-01 · Choi SY, Lee YJ, Kim JM 외 3
- Upregulation of protease-activated receptor-2 in keratinocytes by epidermal vascular endothelial growth factor in vitro and in vivo.
Experimental dermatology · 2017-03 · Lee SH, Kim JM, Lee SE 외 2
- Feasibility of the functional expression of the human organic anion transporting polypeptide 1B1 (OATP1B1) and its genetic variant 521T/C in the mouse liver.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2017-01 · Chae YJ, Lee KR, Lee JH 외 4
- Doxorubicin Regulates Autophagy Signals via Accumulation of Cytosolic Ca2+ in Human Cardiac Progenitor Cells.
International journal of molecular sciences · 2016-10 · Park JH, Choi SH, Kim H 외 5
- Synthesis and SAR studies for the inhibition of TNF-alpha production. Part 2. 2-[3-(Cyclopentyloxy)-4-methoxyphenyl]-substituted-1-isoindolinone derivatives.
Archives of pharmacal research · 2002-04 · Park JS, Moon SC, Baik KU 외 4
- Synthesis and sar studies for the inhibition of tnf-α production. part 2. 2-[3-(cyclopentyloxy)-4-methoxyphenyl]-substituted-1 -isoindolinone derivatives.
Archives of pharmacal research · 2002-04 · Park JS, Moon SC, Baik KU 외 4
- Noble 2-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-isoindolinone derivatives. part I: synthesis and SAR studies for the inhibition of TNF-alpha production.
Archives of pharmacal research · 2001-10 · Park JS, Baik KU, Cho JY 외 3
- Epidermal growth factor (EGF) antagonizes transforming growth factor (TGF)-beta1-induced collagen lattice contraction by human skin fibroblasts.
Biological & pharmaceutical bulletin · 2000-12 · Park JS, Kim JY, Cho JY 외 2
- Synthesis and structure-activity relationships of novel compounds for the inhibition of TNF-alpha production.
Archives of pharmacal research · 2000-08 · Park JS, Balk KU, Son HJ 외 7
- Inhibitory effect of lignans from the rhizomes of Coptis japonica var. dissecta on tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW264.7 cells.
Archives of pharmacal research · 1998-02 · Cho JY, Park J, Yoo ES 외 4
Patents
KIPRIS · applicant-matched- Subsidiary: 대웅테라퓨틱스메트포르민 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 제제, 및 이의 제조 방법
Published · 2025-10 · Application 1020250149073
- Subsidiary: 대웅테라퓨틱스마이크로어레이 제조장치
Published · 2025-08 · Application 1020250122574
- Subsidiary: 대웅테라퓨틱스개선된 안정성 및 투약 편의성을 갖는 레바미피드를 포함하는 조성물
Published · 2025-07 · Application 1020250092556
Registered · 2024-12 · Application 1020240199159
Registered · 2024-11 · Application 1020240167686
Registered · 2024-11 · Application 1020240161445
- Subsidiary: 대웅바이오연속반응 공정을 이용한 이나보글리플로진 합성방법
Registered · 2024-11 · Application 1020240161520
- Subsidiary: 대웅바이오Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
Registered · 2024-11 · Application 1020240161521
- Subsidiary: 대웅바이오분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
Registered · 2024-11 · Application 1020240161522
- Subsidiary: 대웅테라퓨틱스세마글루티드를 포함하는 마이크로어레이 제조용 조성물, 및 상기 조성물로 제조된 마이크로어레이
Registered · 2024-11 · Application 1020240155252
Show 329 more patents
CN · Published · 2024-11 · Application 202480070095.6
TW · Published · 2024-11 · Application 113142168
PCT · Published · 2024-11 · Application PCT/KR2024/017155
- Subsidiary: 대웅테라퓨틱스마이크로어레이 제조장치
Registered · 2024-10 · Application 1020240134509
Registered · 2024-09 · Application 1020240120094
- Subsidiary: 대웅테라퓨틱스개선된 안정성을 갖는 디쿠아포솔을 포함하는 약학 조성물
Published · 2024-07 · Application 1020240090386
Published · 2024-07 · Application 1020240088722
- Subsidiary: 대웅테라퓨틱스안정성이 개선된 피타바스타틴을 포함하는 약학 조성물
Published · 2024-05 · Application 1020240059312
CN · Published · 2024-03 · Application 202480019073.7
TW · Published · 2024-03 · Application 113109769
Published · 2024-03 · Application 1020240036453
EP · Published · 2024-03 · Application 24771216.9
Published · 2023-12 · Application 1020230195128
Published · 2023-12 · Application 1020230195619
- Subsidiary: 대웅테라퓨틱스마이크로니들 어레이 및 이의 제조방법
Rejected · 2023-12 · Application 1020230192751
- Subsidiary: 대웅테라퓨틱스이나보글리플로진을 포함하는 점안제 형태의 약학 조성물
Published · 2023-12 · Application 1020230185355
- Subsidiary: 대웅테라퓨틱스마이크로니들 제조용 조성물
Registered · 2023-11 · Application 1020230158497
Published · 2023-11 · Application 1020230151397
- Subsidiary: 대웅테라퓨틱스마이크로니들 어레이 및 이의 제조방법
Rejected · 2023-10 · Application 1020230136619
- Subsidiary: 대웅테라퓨틱스판크레아틴 및 알칼리화제를 포함하는 약학적 조성물
Published · 2023-09 · Application 1020230130470
Registered · 2023-08 · Application 1020230112977
Registered · 2023-08 · Application 1020230111967
- Subsidiary: 대웅테라퓨틱스인성장호르몬을 포함하는 마이크로구조체 및 이의 제조방법
Published · 2023-08 · Application 1020230111524
- Subsidiary: 대웅테라퓨틱스마이크로 파티클 제조방법 및 상기 제조방법으로 제조된 마이크로 파티클
Registered · 2023-07 · Application 1020230093806
- Subsidiary: 대웅바이오METHOD FOR PRODUCING BENZOAMINE DERIVATIVE
PCT · Published · 2023-06 · Application PCT/KR2023/008635
- Subsidiary: 대웅테라퓨틱스3-하이드록시 니클로사마이드를 포함하는 혈관 또는 판막 석회화 질환의 예방 또는 치료용 조성물
Registered · 2023-06 · Application 1020230070740
- Subsidiary: 대웅테라퓨틱스타이로신 키나아제 억제 활성을 포함하는 신규 화합물 및 이의 용도
Rejected · 2023-04 · Application 1020230051635
- Subsidiary: 대웅테라퓨틱스핵 수용체의 저해 또는 분해를 유도하는 신규 화합물
Rejected · 2023-03 · Application 1020230037846
- Subsidiary: 대웅테라퓨틱스장 정결용 조성물
Published · 2023-03 · Application 1020230035429
- Subsidiary: 대웅테라퓨틱스라베프라졸 및 탄산수소나트륨을 포함하는 약학적 조성물
Rejected · 2023-02 · Application 1020230022161
- Subsidiary: 대웅테라퓨틱스안정성이 개선된 보툴리눔 독소를 포함하는 조성물 및 이를 포함하는 마이크로구조체
Registered · 2023-01 · Application 1020230001761
Registered · 2022-11 · Application 1020220161677
Registered · 2022-10 · Application 1020220140228
Registered · 2022-10 · Application 1020220140227
- Subsidiary: 대웅테라퓨틱스SGLT-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물
Registered · 2022-08 · Application 1020220107682
Registered · 2022-08 · Application 1020220104013
- Subsidiary: 대웅테라퓨틱스이나보글리플로진을 포함하는 안질환의 예방 또는 치료용 약학적 조성물
Registered · 2022-07 · Application 1020220082725
- Subsidiary: 대웅테라퓨틱스이미다졸 유도체를 포함하는 안질환의 예방 또는 치료용 조성물 및 이의 용도
Rejected · 2022-07 · Application 1020220082607
- Subsidiary: 대웅바이오벤조아민 유도체의 제조방법
Registered · 2022-06 · Application 1020220076094
Registered · 2022-05 · Application 1020220055695
US · Published · 2022-02 · Application 18264307
EP · Registered · 2022-02 · Application 22750072.5
- Subsidiary: 대웅테라퓨틱스마이크로니들 제조방법
Registered · 2022-01 · Application 1020220013346
- Subsidiary: 대웅테라퓨틱스마이크로니들 어레이의 제조방법
Registered · 2022-01 · Application 1020220013392
- Subsidiary: 대웅테라퓨틱스마이크로니들 제조방법
Registered · 2021-12 · Application 1020210178684
Rejected · 2021-12 · Application 1020210174960
- Subsidiary: 대웅테라퓨틱스마이크로니들 조립체
Registered · 2021-12 · Application 1020210174179
- Subsidiary: 대웅테라퓨틱스SGLT-2 억제제를 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물
Registered · 2021-12 · Application 1020210171996
- Subsidiary: 대웅테라퓨틱스콘타입 분리형 마이크로니들
Withdrawn · 2021-11 · Application 1020210155755
Registered · 2021-11 · Application 1020210154437
Registered · 2021-11 · Application 1020210154438
- Subsidiary: 대웅테라퓨틱스니클로사마이드를 포함하는 항-메르스 코로나바이러스 조성물
Rejected · 2021-09 · Application 1020210123979
- Subsidiary: 대웅테라퓨틱스마이크로니들 어레이 및 이의 제조방법
Rejected · 2021-09 · Application 1020210123489
- Subsidiary: 대웅테라퓨틱스니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
Registered · 2021-09 · Application 1020210119754
- Subsidiary: 대웅테라퓨틱스마이크로니들 어레이 및 이의 제조방법
Rejected · 2021-09 · Application 1020210116881
PCT · Published · 2021-08 · Application PCT/KR2021/011292
Registered · 2021-04 · Application 1020210055961
- Subsidiary: 대웅테라퓨틱스니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
Registered · 2021-04 · Application 1020210046190
Registered · 2021-02 · Application 1020210017390
Registered · 2020-12 · Application 1020200189195
- Subsidiary: 대웅테라퓨틱스니클로사마이드를 포함하는 섬유증의 예방 및 치료용 조성물
Abandoned · 2020-12 · Application 1020200174675
Rejected · 2020-09 · Application 1020200124348
Registered · 2020-06 · Application 1020200073153
- Subsidiary: 대웅테라퓨틱스프로톤 펌프 저해제 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 및 이의 제조방법
Registered · 2020-04 · Application 1020200046836
- Subsidiary: 대웅테라퓨틱스마이크로니들 어레이 및 이의 제조방법
Rejected · 2020-02 · Application 1020200016332
- Subsidiary: 대웅테라퓨틱스니클로사마이드를 포함하는 관절염 예방 및 치료용 조성물
Registered · 2019-12 · Application 1020190167944
Registered · 2019-12 · Application 1020190161646
- Subsidiary: 대웅테라퓨틱스니클로사마이드 및 디옥타헤드랄 스멕타이트를 포함하는 염증성 장 질환 예방 및 치료용 조성물
Withdrawn · 2019-07 · Application 1020190089386
- Subsidiary: 대웅테라퓨틱스리팍시민 및 디옥타헤드랄 스멕타이트를 포함하는 염증성 장 질환 예방 및 치료용 조성물
Withdrawn · 2019-07 · Application 1020190088899
- Subsidiary: 대웅테라퓨틱스리팍시민 및 니클로사마이드를 포함하는 염증성 장 질환 예방 및 치료용 조성물
Withdrawn · 2019-07 · Application 1020190088898
JP · Registered · 2019-06 · Application 31118235
JP · Published · 2019-06 · Application 31105171
JP · Registered · 2019-06 · Application 31105170
Registered · 2018-08 · Application 1020180100645
Registered · 2018-08 · Application 1020180100644
CN · Published · 2018-04 · Application 201880026176.0
- Subsidiary: 대웅바이오Method for bile acid derivative by using continuous flow reaction
US · Registered · 2018-04 · Application 16606446
- Subsidiary: 대웅바이오연속흐름반응을 이용한 담즙산 유도체의 제조 방법
Registered · 2018-04 · Application 1020197029945
EP · Registered · 2018-04 · Application 18786942.5
PCT · Published · 2018-04 · Application PCT/KR2018/004639
US · Registered · 2017-10 · Application 16477889
EP · Registered · 2017-10 · Application 17892821.4
PCT · Published · 2017-10 · Application PCT/KR2017/011438
JP · Registered · 2017-10 · Application 31539817
Registered · 2017-06 · Application 1020170083174
Rejected · 2017-06 · Application 1020170083178
Registered · 2017-03 · Application 1020170039023
Rejected · 2017-03 · Application 1020170039024
Registered · 2017-01 · Application 1020170009727
JP · Published · 2016-04 · Application 29524477
JP · Published · 2016-04 · Application 29524476
JP · Published · 2016-04 · Application 29524478
Registered · 2016-02 · Application 1020160019573
Rejected · 2016-01 · Application 1020160011143
Rejected · 2016-01 · Application 1020160011142
Rejected · 2016-01 · Application 1020160010623
Registered · 2015-12 · Application 1020150187563
Registered · 2015-11 · Application 1020150168196
Registered · 2015-04 · Application 1020150059655
Registered · 2015-04 · Application 1020150059656
Registered · 2015-04 · Application 1020150059654
Registered · 2015-04 · Application 1020150052693
Registered · 2014-10 · Application 1020140143031
Rejected · 2014-10 · Application 1020140143032
Registered · 2014-03 · Application 1020140036839
Registered · 2014-03 · Application 1020140036802
Registered · 2014-03 · Application 1020140036742
Registered · 2014-03 · Application 1020140036822
Registered · 2014-03 · Application 1020140036763
Expired · 2014-02 · Application 1020140022910
Registered · 2013-10 · Application 1020130131181
- Subsidiary: 대웅테라퓨틱스신규한 항진균성 옥소다이하이드로피리딘카보하이드라자이드 유도체
Registered · 2013-10 · Application 1020130125626
Registered · 2013-08 · Application 1020130092024
Registered · 2012-11 · Application 1020120126963
Rejected · 2011-06 · Application 1020110059030
Rejected · 2010-05 · Application 2020100004932
CN · Published · 2010-03 · Application 201080013954
EP · Registered · 2010-03 · Application 10756377.7
PCT · Published · 2010-03 · Application PCT/KR2010/001867
- Subsidiary: 대웅바이오Improved method for preparing meropenem using zinc powder
CN · Published · 2010-03 · Application 201080011897
- Subsidiary: 대웅바이오IMPROVED METHOD FOR PREPARING MEROPENEM USING ZINC POWDER
EP · Registered · 2010-03 · Application 10751027.3
- Subsidiary: 대웅바이오IMPROVED METHOD FOR PREPARING MEROPENEM USING ZINC POWDER
PCT · Published · 2010-03 · Application PCT/KR2010/001516
- Subsidiary: 대웅바이오Process for the preparation of atorvastatin
TW · Published · 2008-10 · Application 097140797
- Subsidiary: 대웅바이오PROCESS FOR THE PREPARATION OF ATORVASTATIN
PCT · Published · 2008-10 · Application PCT/KR2008/006290
Rejected · 2008-10 · Application 1020080099336
Registered · 2008-09 · Application 1020080088475
Expired · 2008-08 · Application 1020080079614
Rejected · 2007-03 · Application 1020070027558
EP · Registered · 2006-10 · Application 06812242.3
PCT · Published · 2006-10 · Application PCT/KR2006/004401
Registered · 2006-10 · Application 1020060097734
Expired · 2006-09 · Application 2020060027335
Expired · 2006-09 · Application 2020060027336
Registered · 2006-08 · Application 1020060072809
- Subsidiary: 대웅바이오PURIFICATION PROCESS FOR CHENODEOXYCHOLIC ACID
EP · Registered · 2006-07 · Application 06783458.0
- Subsidiary: 대웅바이오PURIFICATION PROCESS FOR CHENODEOXYCHOLIC ACID
EP · Registered · 2006-07 · Application 06783444.0
EP · Registered · 2006-07 · Application 06769186.5
PCT · Published · 2006-07 · Application PCT/KR2006/002640
Registered · 2006-06 · Application 1020060059174
Expired · 2006-05 · Application 2020060014185
Expired · 2006-04 · Application 2020060010196
Registered · 2006-04 · Application 1020060032391
Rejected · 2006-02 · Application 1020087021147
Expired · 2005-12 · Application 1020050123494
Expired · 2005-11 · Application 1020050108344
Expired · 2005-11 · Application 2020050031141
Expired · 2005-09 · Application 1020050089785
Expired · 2005-09 · Application 1020050085718
Expired · 2005-09 · Application 1020050084864
Expired · 2005-05 · Application 1020050046381
Expired · 2004-12 · Application 1020040115526
Expired · 2004-10 · Application 2020040028379
EP · Registered · 2004-06 · Application 04736706.5
PCT · Published · 2004-06 · Application PCT/KR2004/001393
Expired · 2004-05 · Application 1020040031977
Expired · 2003-10 · Application 1020030070421
Expired · 2003-09 · Application 1020030067971
Withdrawn · 2003-09 · Application 1020030065575
Expired · 2003-09 · Application 1020030063732
Expired · 2003-04 · Application 1020030023130
Expired · 2003-04 · Application 1020030020982
Expired · 2003-03 · Application 1020030014086
Expired · 2003-02 · Application 1020030009875
Rejected · 2003-02 · Application 1020030008818
Expired · 2002-11 · Application 1020020068496
Expired · 2002-10 · Application 1020020060151
Rejected · 2002-09 · Application 1020020057078
Expired · 2002-09 · Application 1020020056585
Rejected · 2002-08 · Application 1020020052061
Expired · 2002-08 · Application 1020020045585
Expired · 2002-05 · Application 1020020030438
Expired · 2002-05 · Application 1020020028505
Expired · 2001-12 · Application 1020010080806
Rejected · 2001-09 · Application 1020010054590
Withdrawn · 2001-08 · Application 1020010049259
Expired · 2001-08 · Application 1020010048647
Expired · 2001-08 · Application 1020010046910
Expired · 2001-04 · Application 1020037013005
Rejected · 2000-12 · Application 1020000081212
Expired · 2000-10 · Application 1020000058127
Rejected · 2000-05 · Application 1020000028285
Expired · 2000-04 · Application 1020000021313
Expired · 2000-03 · Application 1020000017011
Expired · 2000-03 · Application 1020000015250
Expired · 2000-02 · Application 1020000008116
Expired · 1999-12 · Application 1019990061030
Expired · 1999-12 · Application 1019990057742
Expired · 1999-12 · Application 1019990057743
Rejected · 1999-12 · Application 1019990057910
Abandoned · 1999-10 · Application 1019990047721
Expired · 1999-09 · Application 1019990040831
Abandoned · 1999-08 · Application 1019990033226
Expired · 1999-06 · Application 1020007014775
Withdrawn · 1999-06 · Application 1019990025143
Expired · 1999-06 · Application 1020017016389
Abandoned · 1999-06 · Application 1019990021642
Expired · 1999-04 · Application 1020017000075
Expired · 1999-04 · Application 1019990013635
Expired · 1999-01 · Application 1019990000048
Withdrawn · 1998-12 · Application 1019980063716
Expired · 1998-12 · Application 1019980063713
Expired · 1998-08 · Application 1019980033463
Expired · 1998-08 · Application 1019980033305
Expired · 1998-05 · Application 1019980017926
Expired · 1998-03 · Application 1019980011379
Expired · 1998-03 · Application 1019980010020
Expired · 1998-03 · Application 1019980006865
Expired · 1997-12 · Application 1019970077659
Expired · 1997-12 · Application 1019970077660
Expired · 1997-11 · Application 1019970057603
Expired · 1997-09 · Application 1019970046543
Expired · 1997-09 · Application 1019970045842
Expired · 1997-07 · Application 2019970019528
Expired · 1997-07 · Application 1019970032600
Expired · 1997-05 · Application 1019970019262
Expired · 1997-03 · Application 1019970011765
Rejected · 1997-03 · Application 1019970011959
Withdrawn · 1997-03 · Application 1019970011951
Rejected · 1997-03 · Application 1019970011960
Withdrawn · 1997-03 · Application 1019970011950
Rejected · 1997-03 · Application 1019970009706
Expired · 1997-03 · Application 1019970007512
Expired · 1997-01 · Application 1019970002700
Expired · 1997-01 · Application 1019970002133
Expired · 1997-01 · Application 1019970000373
Rejected · 1996-12 · Application 1019960070739
Abandoned · 1996-11 · Application 1019960053539
Rejected · 1996-09 · Application 1019960038107
Expired · 1996-08 · Application 1019960033814
Expired · 1996-07 · Application 1019960030670
Expired · 1996-05 · Application 1019960016951
Abandoned · 1996-04 · Application 1019960012072
Expired · 1996-03 · Application 1019960008230
Expired · 1996-03 · Application 1019960008229
Abandoned · 1996-03 · Application 1019960008228
Rejected · 1996-03 · Application 1019960008231
Expired · 1996-03 · Application 1019960008393
Abandoned · 1996-03 · Application 1019960006948
Expired · 1996-02 · Application 1019960004402
Abandoned · 1996-01 · Application 1019960001445
Expired · 1996-01 · Application 1019960001553
Rejected · 1996-01 · Application 1019960000798
Rejected · 1995-12 · Application 1019950066329
Expired · 1995-08 · Application 1019950025763
Abandoned · 1995-06 · Application 1019950014541
Expired · 1995-04 · Application 1019950009439
Expired · 1995-04 · Application 1019950009440
Expired · 1995-03 · Application 1019950006225
Expired · 1995-03 · Application 1019950006224
Rejected · 1995-02 · Application 1019950002162
Rejected · 1995-02 · Application 1019950002161
Abandoned · 1994-12 · Application 1019940032997
Abandoned · 1994-12 · Application 1019940032996
Rejected · 1994-11 · Application 1019940030052
Expired · 1994-11 · Application 1019940030053
Expired · 1994-11 · Application 1019940029953
Expired · 1994-11 · Application 1019940028547
Expired · 1994-10 · Application 1019940027565
Expired · 1994-09 · Application 1019940024214
Expired · 1994-07 · Application 1019940018725
Expired · 1994-06 · Application 1019940014117
Rejected · 1994-06 · Application 1019940013605
Expired · 1994-06 · Application 1019940013601
Rejected · 1994-06 · Application 1019940013606
Withdrawn · 1994-04 · Application 1019940008963
Expired · 1993-12 · Application 1019930030435
Expired · 1993-12 · Application 1019930030434
Expired · 1993-12 · Application 1019930030436
Withdrawn · 1993-12 · Application 1019930029096
Expired · 1993-05 · Application 1019930009163
Expired · 1993-05 · Application 1019930008779
Expired · 1993-05 · Application 1019930008780
Expired · 1993-05 · Application 1019930007614
Expired · 1993-04 · Application 1019930007416
Expired · 1993-04 · Application 1019930007095
Expired · 1993-04 · Application 1019930007094
Expired · 1993-04 · Application 1019930006979
Expired · 1993-04 · Application 1019930006978
Expired · 1993-04 · Application 1019930006981
Expired · 1993-04 · Application 1019930006980
Rejected · 1993-03 · Application 1019930005316
Expired · 1993-01 · Application 1019930000752
Expired · 1993-01 · Application 1019930000754
Expired · 1993-01 · Application 1019930000753
Expired · 1992-12 · Application 1019920025428
Expired · 1992-09 · Application 1019920016516
Expired · 1992-07 · Application 1019920013813
Expired · 1992-07 · Application 1019920012474
Expired · 1992-06 · Application 1019920010459
Expired · 1992-05 · Application 1019920007952
Expired · 1992-04 · Application 1019920006242
Expired · 1992-04 · Application 1019920005534
Rejected · 1992-03 · Application 1019920003407
Withdrawn · 1991-12 · Application 1019910025863
Rejected · 1991-10 · Application 1019910017164
Expired · 1991-07 · Application 1019910012969
Expired · 1991-07 · Application 1019910012105
Expired · 1991-06 · Application 1019910010561
Expired · 1991-06 · Application 1019910010560
Expired · 1991-05 · Application 1019910008525
Expired · 1991-02 · Application 1019910003397
Expired · 1991-01 · Application 1019910000994
Expired · 1990-12 · Application 1019900019967
Rejected · 1990-05 · Application 1019900007390
Abandoned · 1990-04 · Application 1019900004857
Rejected · 1989-06 · Application 1019890008719
Expired · 1989-03 · Application 1019890003214
Expired · 1989-02 · Application 1019890001949
Withdrawn · 1988-10 · Application 1019880013743
Rejected · 1988-06 · Application 2019880008659
Expired · 1988-05 · Application 1019880006075
Rejected · 1988-05 · Application 1019880005382
Rejected · 1988-02 · Application 1019880001987
Rejected · 1987-12 · Application 1019870014463
Rejected · 1986-11 · Application 1019860009893
Rejected · 1986-08 · Application 1019860007052
Abandoned · 1985-10 · Application 1019850007597
Expired · 1985-05 · Application 1019850003491
Rejected · 1984-08 · Application 1019840004603
Expired · 1984-01 · Application 1019840000330
Expired · 1984-01 · Application 1019840000118
Withdrawn · 1984-01 · Application 1019840000012
Withdrawn · 1983-10 · Application 1019830005041
Expired · 1983-09 · Application 1019830004152
Expired · 1983-08 · Application 1019830004024
Abandoned · 1983-07 · Application 1019830003572
Expired · 1983-06 · Application 1019830002970
Expired · 1982-05 · Application 1019820002080
Expired · 1979-04 · Application 2019790002134
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot37
- PerplexityPerplexityBot2
- GoogleGoogleOther2
- AnthropicClaudeBot2
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for DAEWOONG CO.,LTD and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
Founded in 2010 and KOSDAQ-listed in 2018, Dynamic Solution makes AI/IoT-based rehabilitation devices like the Rapael Smart Glove.
Interojo, founded 2000 and KOSDAQ-listed 2010, manufactures contact lenses under its Clalen brand domestically and via OEM/ODM overseas.
MITECH CO.,LTD., founded in 1991 and listed on KOSDAQ in 2018, makes non-vascular stents and distributes Fujifilm endoscopy equipment.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
Founded in 2000 and KOSDAQ-listed in 2013, Corentec makes artificial joints; hip and knee implants exceed 85% of revenue.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
Founded in 2010 and KOSDAQ-listed in 2018, Sejong Medical manufactures laparoscopic surgical instruments.
Founded in 2012 and listed on KOSDAQ in 2026, REMEDI develops portable X-ray imaging devices based on its low-dose, miniaturized X-ray technology.
KOSDAQ-listed medical device company developing the LOTUS and HELIOS laser aesthetic devices and the PALLAS vitiligo treatment device.
Develops quantitative fluorescence biomarker technology for oral disease diagnostic devices.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition